Navigation Links
2009 H1N1 vaccine protects against 1918 influenza virus
Date:6/15/2010

Researchers at Mount Sinai School of Medicine have determined people who were vaccinated against the 2009 H1N1 influenza virus may also be protected against the lethal 1918 Spanish influenza virus, which killed more than 50 million people worldwide. The new findings are published in the current issue of Nature Communications.

"While the reconstruction of the formerly extinct Spanish influenza virus was important in helping study other pandemic viruses, it raised some concerns about an accidental lab release or its use as a bioterrorist agent," said Adolfo Garcia-Sastre, PhD, Professor, Microbiology, Mount Sinai School of Medicine, lead investigator on the study. "Our research shows that the 2009 H1N1 influenza vaccine protects against the Spanish influenza virus, an important breakthrough in preventing another devastating pandemic like 1918." Other Mount Sinai School of Medicine groups involved in the study include the laboratories of Dr. Palese and Dr. Basler. The study was also done in collaboration with the group of Dr. Belshe, at St. Louis University, who provided the human vaccination samples.

The researchers administered to three groups of mice either the 2009 H1N1 influenza vaccine, the seasonal influenza vaccine, or no vaccine at all. Twenty-one days later, the mice were exposed to a lethal dose of the 1918 Spanish influenza virus. The mice receiving the H1N1 vaccine were the only ones to survive, while also exhibiting limited morbidity following the vaccination.

Additionally, Dr. Garcia-Sastre's team injected the mice with blood serum taken from humans who had been vaccinated against 2009 H1N1 influenza. Later, the mice were given a potent dose of the 1918 Spanish influenza virus. Researchers found that the antibodies in the blood produced by the 2009 H1N1 vaccine may also protect against the 1918 Spanish influenza virus.

"Considering the millions of people who have already been vaccinated against 2009 H1N1 influenza, cross-protection against the 1918 influenza virus may be widespread. Our research indicates that people who were exposed to the virus may also be protected," said Dr. Garcia-Sastre. "We look forward to conducting further research on the benefits of the 2009 H1N1 influenza vaccine in protecting against the deadly 1918 Spanish influenza virus."


'/>"/>

Contact: Mount Sinai Press Office
newsnow@mountsinai.org
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related biology news :

1. New discovery could aid development of elusive bovine mastitis vaccine
2. New bacterial signaling molecule could lead to improved vaccines
3. MSU researchers testing vaccine to help people quit smoking
4. New steps toward a universal flu vaccine
5. Cutting-edge vaccine research to be showcased at AAPS National Biotechnology Conference
6. Texas Childrens Hospital vaccine experts present 4 studies
7. Prescription drug could boost effects of vaccines for HIV and other diseases
8. Vaccines preventing pneumococcal disease protect African children with sickle-cell disease
9. GEN reports on the promise of DNA vaccines
10. Researchers use novel nanoparticle vaccine to cure type 1 diabetes in mice
11. Workshop on R&D for rapid vaccine development and production in Asia/Australia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2017)... SAN MATEO, Calif. , March 6, 2017 ... predictive marketing and sales technology, today announced Predictive ... (AI) solution for infusing actionable sales intelligence into ... customers to automatically enable their sales organizations with ... contextual messages that allow for intelligent engagement. Predictive ...
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:3/2/2017)... , March 2, 2017 Australian stem ... (ASX: CYP), has signed an agreement with the ... the Monash Biomedicine Discovery Institute and Department of Pharmacology ... conduct a further preclinical study to support the use ... of asthma.  Asthma is a chronic, ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... , March 23, 2017 According to a ... and derivatives market is fragmented due to the presence of a large ... Proliant, Thermo Fisher , and Sigma-Aldrich, compete with each other ... companies, collectively, held more than 76% of this market in 2016.  ... As of now, ...
(Date:3/23/2017)... , March 23, 2017 In ... four equities in the Biotech industry: Sangamo Therapeutics Inc. ... Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. (NASDAQ: ... , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from ... their free report at: ...
(Date:3/22/2017)... 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today ... (RGC), U.K. Biobank and GSK to generate genetic sequence data ... The initiative will enable researchers to gain valuable insights to ... wide range of serious and life threatening diseases. ... Genetic evidence ...
Breaking Biology Technology: